Bicyclic Urea Kinase Inhibitors for Selective JAK2 V617F Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK2 small molecule inhibitors targeting the JAK2 kinase (JH1) domain fail to selectively target the JAK2 V617F mutant, which is associated with myeloproliferative neoplasms, while sparing essential JAK2 functions.
Innovation Solution
Development of bicyclic urea compounds that modulate the activity of the JAK2 kinase, specifically targeting the JAK2 V617F mutant, thereby inhibiting its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current JAK2 small molecule inhibitors targeting the JAK2 kinase (JH1) domain are used, then JAK2 activity is inhibited, but selectivity for the V617F mutant over wild-type JAK2 is lost
Solution Approach 1:
The patent applies local quality by designing the bicyclic urea compound to specifically interact with the unique structural features of the V617F mutant at the pseudokinase domain, while the remainder of the JAK2 kinase domain remains unaffected. This localized targeting approach allows selective inhibition of the mutant without disrupting wild-type JAK2 function.
Solution Approach 2:
The bicyclic urea compound acts as an intermediary that bridges the ATP-binding pocket and the pseudokinase domain, forming specific interactions with the V617F mutation site. This intermediary molecule enables selective binding to the mutant form while maintaining the ability to preserve essential wild-type functions through controlled interaction mechanisms.
2Reliability
If JAK2 kinase (JH1) domain is targeted to inhibit JAK2 activity, then disease progression is slowed, but essential JAK2 signaling functions are compromised
Solution Approach 1:
The patent segments the JAK2 kinase into functionally distinct regions: the catalytic JH1 domain and the regulatory pseudokinase JH2 domain. By designing the bicyclic urea compound to primarily interact with the pseudokinase domain where the V617F mutation occurs, the therapy achieves selective inhibition without compromising essential catalytic functions in the JH1 domain.
Solution Approach 2:
The patent utilizes parameter changes by modifying the chemical structure to create a bicyclic urea compound with specific binding affinity for the V617F mutant conformation. This structural parameter change enables the compound to distinguish between mutant and wild-type JAK2, achieving therapeutic efficacy while preserving essential functions through selective parameter-based recognition.
Data Source
AI summary
The present application provides bicyclic urea compounds that modulate the activity of JAK2, which are useful in the treatment of various diseases, including cancer.